1. Generics Bulletin
  2. >>Products
  3. >>Generics

Three Not A Magic Number For Mayne With Another NuvaRing CRL

Follows CRLs Handed Out By US FDA To Australian Firm In 2018 And 2020

 
• By Dean Rudge

Australia’s Mayne Pharma has announced another complete response letter for its proposed generic version of Organon’s NuvaRing (etonogestrel/ethinylestradiol) contraceptive device, marking a trio of setbacks for the ANDA product.

Three Fingers Hand Sky
Mayne has received a third CRL over its NuvaRing rival • Source: Alamy

Mayne Pharma’s proposed generic version of Organon’s NuvaRing (etonogestrel/ethinylestradiol) contraceptive device in the US is proving to be something of an albatross for the company, with the US Food and Drug Administration once again issuing a complete response letter detailing that it cannot approve the firm’s application in its current form.

The Australian firm said it was “working closely with its development partner, Mithra, and the FDA to address the questions...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

Aye Or Nay To Biosimilars For Sun Amid US Regulatory Easing?

 
• By Anju Ghangurde

Sun’s specialty gambit reaps gains with US sales surpassing generics for the first time in Q2 FY26, but will it finally enter the fray for biosimilars as the US moves to simplify regulatory requirements in the segment?

US FDA ANDA Priority Pilot ‘Practically Unusable’ Without Tweaks, AAM CEO Says

 
• By Sarah Karlin-Smith

Association for Accessible Medicines CEO John Murphy says the FDA may need to consider phasing in the requirements for the new ANDA priority voucher incentive program if it wants sponsors to apply in the near-term.

Lupin Sets Out Five-Year Plan For US Biosimilars With Revenue Contributions Expected From FY2027

 
• By Urtė Fultinavičiūtė

Favorable regulatory winds in the US are leading Lupin down the biosimilar path, as it also hopes that the potential US generic-first policy will boost its wider off-patent drug portfolio. However, it is also facing several facility compliance setbacks.

NICE Breaks New Ground In England As Abiraterone Becomes First Generic Drug To Win Funding

 
• By Neena Brizmohun

As more medicines come off patent in the coming years, the UK generics and biosimilars industry association is hoping to see more generic products evaluated for reimbursement by the health technology assessment institute, NICE.

More from Products

NICE Breaks New Ground In England As Abiraterone Becomes First Generic Drug To Win Funding

 
• By Neena Brizmohun

As more medicines come off patent in the coming years, the UK generics and biosimilars industry association is hoping to see more generic products evaluated for reimbursement by the health technology assessment institute, NICE.

Aurobindo On Easier US Biosimilar Pathway, Zentiva Miss And Deal Strategy

 
• By Vibha Ravi

Do US FDA’s efforts at simplifying the biosimilar pathway create more competition and threaten Aurobindo Pharma's return on investments? Management speaks on this, biosimilar filing plans and deal strategy at the Q2 FY26 earnings call.

Hikma Teams With Mark Cuban’s Cost Plus For US Ustekinumab Launch

 
• By Dave Wallace

Hikma has set out expectations for its nascent biosimilars business in the US, after launching its Bio-Thera-partnered Starjezma rival to Stelara through Mark Cuban’s Cost Plus Drug Company. Meanwhile, a trading update issued by the firm has pointed to a slight decline in Injectables margins.